Currently out of the existing stock ratings of David Westenberg, 112 are a BUY (63.28%), 59 are a HOLD (33.33%), 6 are a SELL (3.39%).

David Westenberg

Work Performance Price Targets & Ratings Chart

Analyst David Westenberg, currently employed at PIPER SANDLER, carries an average stock price target met ratio of 64.27% that have a potential upside of 21.22% achieved within 150 days.

David Westenberg’s has documented 359 price targets and ratings displayed on 24 stocks. The coverage is on Healthcare, Financial Services sectors.

Most recent stock forecast was given on PACB, Pacific Biosciences of California at 11-Aug-2025.

Wall Street Analyst David Westenberg

Analyst best performing recommendations are on OCX (ONCOCYTE CORP).
The best stock recommendation documented was for OCX (ONCOCYTE CORP) at 11/13/2023. The price target of $3 was fulfilled within 1 day with a profit of $0.24 (8.7%) receiving and performance score of 86.96.

Average potential price target upside

of $59.75 (25.69%) on ILMN (ILLUMINA).
of $45.1 (11.45%) on IDXX (IDEXX LABORATORIES).
of $28.16 (68.56%) on NTRA (NATERA).

FLGT Fulgent Genetics HSKA Heska ILMN Illumina ADPT Adaptive Biotechnologies Corp AKYA Akoya Biosciences ELAN Elanco Animal Health EXAS EXACT Sciences GH Guardant Health IDXX IDEXX Laboratories NEO NeoGenomics NTRA Natera NVTA Invitae Corp OCX OncoCyte Corp PACB Pacific Biosciences of California PETQ PetIQ TRUP Trupanion CTKB Cytek Biosciences ZTS Zoetis CVET Covetrus NEOG Neogen DGX Quest Diagnostics LH Laboratory of America Holdings TEM Tempus AI, Common Stock KIN Kindred Biosciences

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

David Westenberg (PIPER SANDLER)